Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

2.97USD
13 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.97
Open
$3.14
Day's High
$3.19
Day's Low
$2.96
Volume
135,383
Avg. Vol
232,778
52-wk High
$14.70
52-wk Low
$1.46

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Announces Strategic Review
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS ANNOUNCES STRATEGIC REVIEW.ABEONA THERAPEUTICS INC - COMPANY ENGAGES JEFFERIES LLC IN RESPONSE TO STRATEGIC INBOUND INTEREST.ABEONA THERAPEUTICS INC - INITIATED STRATEGIC ALTERNATIVES, INCLUDING, BUT NOT LIMITED TO PARTNERING OF ITS VARIOUS CLINICAL AND PRE-CLINICAL PROGRAMS.ABEONA THERAPEUTICS INC - STRATEGIC ALTERNATIVES ALSO INCLUDE SALE OR MERGER OF COMPANY.  Full Article

Abeona Therapeutics Expects To Initiate Vital Phase 3 Trial For Its Eb-101 Program In Q4 Of 2019
Thursday, 25 Jul 2019 

July 25 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS INC - EXPECTS TO INITIATE VITAL PHASE 3 TRIAL FOR ITS EB-101 PROGRAM IN Q4 OF 2019..ABEONA THERAPEUTICS INC - RECENTLY HELD A MEETING WITH FDA TO DISCUSS PREPARATIONS FOR UPCOMING VITAL PHASE 3 CLINICAL TRIAL FOR EB-101.ABEONA THERAPEUTICS INC - RECEIVED FEEDBACK FROM FDA AND IS CURRENTLY WORKING THROUGH OUTSTANDING ITEMS WITH AGENCY.  Full Article

Abeona Therapeutics Announces Positive Interim Data From The ABO-102 Phase 1/2 Gene Therapy Clinical Trial In MPS IIIA
Thursday, 25 Jul 2019 

July 25 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM THE ABO-102 PHASE 1/2 GENE THERAPY CLINICAL TRIAL IN MPS IIIA.ABEONA THERAPEUTICS INC - RMAT MEETING ANTICIPATED FOR 2H2019 TO DISCUSS NEXT STEPS.ABEONA THERAPEUTICS INC - ROBUST AND SUSTAINED BIOMARKER IMPROVEMENT ACROSS ALL DOSE COHORTS WITH 8 MONTHS TO 2 YEARS OF FOLLOW UP.ABEONA THERAPEUTICS INC - NO PRODUCT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED TO DATE..  Full Article

Abeona Therapeutics Receives FDA Fast Track Designation For ABO-202 AAV9 Gene Therapy In CLN1 Disease
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR ABO-202 AAV9 GENE THERAPY IN CLN1 DISEASE.ABEONA THERAPEUTICS INC - ABEONA IS PREPARING TO INITIATE A PHASE 1/2 CLINICAL TRIAL EVALUATING ABO-202 IN PATIENTS WITH CLN1 DISEASE.ABEONA THERAPEUTICS INC - WILL PROVIDE GUIDANCE ON TIMING OF TRIAL LATER THIS YEAR..  Full Article

Abeona Therapeutics Appoints João Siffert Chief Executive Officer
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS APPOINTS JOÃO SIFFERT, M.D. CHIEF EXECUTIVE OFFICER.ABEONA THERAPEUTICS INC - SIFFERT HAS SERVED AS INTERIM CEO SINCE NOVEMBER OF LAST YEAR..ABEONA THERAPEUTICS INC - SIFFERT WILL RETAIN HIS RESPONSIBILITIES AS HEAD OF RESEARCH AND DEVELOPMENT AND CMO UNTIL A CLINICAL DEVELOPMENT LEAD IS IDENTIFIED..  Full Article

VOGO And ABEO Sign Partnership Agreement To Deliver New Service Offering For Abeo’S Clients
Monday, 21 Jan 2019 

Jan 21 (Reuters) - VOGO SAS ::ABEO AND VOGO SIGN PARTNERSHIP AGREEMENT.ABEO AND VOGO ARE COMBINING THEIR EXPERTISE TO DELIVER A NEW SERVICE OFFERING FOR ABEO’S CLIENTS.NEW SOLUTION, WHICH IS TO UNDERGO COMMERCIAL VALIDATION IN THE FIRST HALF OF 2019, COULD ULTIMATELY PAVE THE WAY TO AN INTERNATIONAL DISTRIBUTION AGREEMENT.  Full Article

Abeona Therapeutics Appoints Christine Silverstein CFO
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS STRENGTHENS FINANCIAL LEADERSHIP WITH NEW EXECUTIVE APPOINTMENTS.ABEONA THERAPEUTICS INC - HAS APPOINTED CHRISTINE SILVERSTEIN TO POSITION OF CHIEF FINANCIAL OFFICER.  Full Article

Abeona Unveils New Cystic Fibrosis Program
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS DETAILS PATHWAY FOR ADVANCING LEAD CLINICAL PROGRAMS AND UNVEILS NEW CYSTIC FIBROSIS PROGRAM BORN FROM NEXT GENERATION AIM™ VECTOR PLATFORM AT 2018 RESEARCH AND DEVELOPMENT DAY.ABEONA THERAPEUTICS INC - EXPANDING PHASE I/II STUDY OF ABO-102 FOR SANFILIPPO SYNDROME TYPE A (MPS IIIA).ABEONA THERAPEUTICS INC - PLANS TO AMEND ITS ONGOING PHASE I/II TRIAL EVALUATING ABO-102 FOR MPS IIIA TO ENROLL PATIENTS AT EARLIER STAGES OF DISEASE.ABEONA THERAPEUTICS INC - ABO-102 HAS BEEN WELL TOLERATED TO DATE WITH NO SERIOUS DRUG-RELATED ADVERSE EVENTS.ABEONA THERAPEUTICS INC - ESTABLISHED GMP MANUFACTURING CAPABILITY FOR EB-101 AT ITS GENE THERAPY MANUFACTURING FACILITY IN CLEVELAND.ABEONA THERAPEUTICS - FACILITY IN CLEVELAND HAS SCALABLE CAPACITY TO SUPPORT POTENTIAL COMMERCIAL LAUNCH OF EB-101.ABEONA THERAPEUTICS INC - EXPECTS TO INITIATE A PIVOTAL CLINICAL TRIAL EVALUATING POTENTIAL OF EB-101 FOR TREATMENT OF RDEB IN MIDDLE OF 2019.  Full Article

Abeona Therapeutics And Regenxbio Announce License Agreement
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS AND REGENXBIO ANNOUNCE WORLDWIDE EXCLUSIVE LICENSES FOR THE TREATMENT OF FOUR RARE LYSOSOMAL STORAGE DISORDERS USING NAV AAV9 VECTOR.ABEONA THERAPEUTICS INC - ABEONA TO PAY REGENXBIO $20 MILLION UPFRONT.ABEONA THERAPEUTICS INC - ABEONA TO PAY REGENXBIO $10 MILLION PAID UPON SIGNING, $10 MILLION BY FIRST ANNIVERSARY OF AGREEMENT.ABEONA THERAPEUTICS INC - ANNUAL PAYMENTS OF $20 MILLION GUARANTEED PAYABLE UPON SECOND ANNIVERSARY OF AGREEMENT.  Full Article

Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
Monday, 2 Apr 2018 

April 2 (Reuters) - Abeona Therapeutics Inc ::APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER.TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER.  Full Article